Kahn Clare 4

What Happened
Clare Kahn, a director of Solid Biosciences, received a grant (derivative option award) covering 77,500 shares on June 10, 2026. The filing reports an acquisition price of $0.00, indicating this was an awarded option/derivative rather than an open‑market purchase. This is a grant of rights to acquire shares in the future — not a sale or exercise.

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-11 (filed one day after the transaction, i.e., timely).
• Transaction type: Award/Grant (derivative instrument) for 77,500 shares; reported price $0.00.
• Shares owned after transaction: Not specified in this Form 4 filing.
• Vesting: The option vests in full on the earlier of the one‑year anniversary of the grant date and immediately prior to the issuer's next annual meeting after the grant; it also vests 100% upon specified change‑in‑control events. (Footnote from filing.)
• Filing timeliness: Reported within the standard SEC Form 4 window (filed the day after the grant).

Context
This was an equity award to a non‑executive director, a routine form of compensation/retention. As a grant (derivative award), it does not by itself indicate buying or selling pressure in the market until the option is exercised or shares are sold. The vesting schedule means the award becomes exercisable or deliverable within about a year or sooner upon a change in control.